This delayed gastric emptying means decongestants, antihistamines, and other oral cold remedies may stay in your stomach longer than usual, potentially increasing their concentration in your bloodstream and intensifying side effects
This compounded preparation: Has not been approved by the FDA Has not undergone FDA review for safety, effectiveness, or quality Is prepared specifically for you based on your prescriber's order Individual outcomes may vary Dosing is determined by the prescribing provider based on patient-specific factors
Always consult a qualified healthcare provider before starting any treatment
We offer a range of complementary and alternative therapies that can help improve overall health and well-being
The incidence varies considerably between different medications and doses: Semaglutide (Ozempic): Vomiting occurs in approximately 5-10% of patients at diabetes doses Semaglutide (Wegovy): At the higher weight management dose (2.4mg), vomiting affects up to 16% of patients Liraglutide (Victoza): Vomiting affects approximately 5% of patients Liraglutide (Saxenda): At weight management doses, vomiting occurs in about 7-10% of patients Dulaglutide (Trulicity): Vomiting affects approximately 7-9% of patients Tirzepatide (Mounjaro): Vomiting occurs in approximately 5-10% of patients, varying by dose These side effects are most pronounced during the initial treatment phase, particularly in the first 48 weeks, and often diminish as the body adapts to the medication